After over one year clinical studies on several female cancer patients with breast surgery, the method was classified into risk-group III (lowest risk), and a review committee was established which surveys the selection of patients and the process of therapy, according to Japanese regulations.
Nikkei Biotech news release, Jan 26, 2015
Shonan Kamakura General Hospital starts offering plastic surgery based on autologous adipose-tissue derived mesenchymal progenitor cells